Prescription Direction in Medical Cannabis:
Guidance for Clinicians and Patients
In the UK, most medical cannabis, legally termed cannabis-based medicinal products (CBPMs), is prescribed by specialists in the private sector. Issues around prescription direction, where patients are steered toward specific pharmacies or restricted product lists, have become critical ethical and professional considerations for the sector.
Three principles that underpin this guidance
Patient Owns the Prescription
Once issued, a valid prescription belongs to the patient — not the clinic. Patients may take it to any appropriately registered pharmacy.
Clinical Grounds Only
Any direction toward a specific pharmacy or product must be clinically justified. Commercial or operational preferences are not sufficient grounds.
Regulatory Accountability
Independent CBPM clinics are regulated by the CQC. Professional conduct is subject to GMC oversight. Patients can raise concerns with either body.
What is "Prescription Direction"?
Key Term
'Prescription Direction' refers to any practice in which a healthcare provider influences or obligates a patient to use a particular pharmacy or dispensing service, or restricts which products may be prescribed based on a clinic's internal formulary rather than clinical considerations alone.
For standard prescription-only medicines, and CBPMs alike, once a valid prescription is issued, the patient, not the issuing clinic or prescriber, owns the prescription and has the right to have it dispensed at any appropriate pharmacy. Professional guidance makes no provision for locking prescriptions to a particular dispensing outlet on non-clinical grounds. [1]
This issue has grown in practical significance as the UK's private medical cannabis sector has expanded. Patients, many managing chronic and complex conditions, must be able to access the most suitable products at pharmacies they can practically use and afford.
Prescribing medical cannabis in the UK
Who Can Prescribe
GMC Specialist Register Only
CBPMs (excluding those with a marketing authorisation like Sativex®) are predominantly unlicensed medicines. The law restricts their prescription to doctors on the GMC's Specialist Register, acting within their area of competence. [3]
Clinic Regulation
Care Quality Commission
Independent clinics prescribing CBPMs are regulated by the CQC, which requires clinical governance, prescriber competence, patient safety, informed consent, and compliance with controlled drugs legislation. [4]
Pharmacy Supply
Any Registered Pharmacy
There is no single official UK "list" of pharmacies for CBPMs. Any pharmacy that is properly registered and complies with regulatory standards may dispense them once presented with a valid prescription. [5]
Unlicensed Medicines and Clinical Responsibility
Unlicensed medicines entail additional responsibilities for prescribers because they have not undergone the full range of regulatory assessments for safety, quality and efficacy. Prescribers must therefore be confident that the product is appropriate for the individual patient, and must explain to patients the unlicensed nature of the treatment as part of informed decision-making. [1][5]
Shared Care Arrangements
NHS England guidance confirms that while subsequent prescriptions may sometimes be made under shared care arrangements, initial prescriptions must be authorised by a specialist clinician. This reinforces the importance of maintaining robust clinical oversight throughout a patient's CBPM treatment pathway. [2]
Conflicts of Interest
The CQC guidance confirms that providers must ensure prescribing decisions are clinically justified, appropriately documented, and made in the best interests of the patient, with systems in place to manage risk and avoid conflicts of interest. This includes ensuring that organisational or commercial arrangements do not compromise professional judgement or patient choice in prescribing or supply pathways. [4]
Responsibilities for prescribing doctors
Many private medical cannabis clinics operate internal formularies, lists of products they commonly prescribe based on clinician familiarity, supply arrangements, or existing protocols. There may be legitimate clinical reasons to prefer certain products (e.g. formulations with established pharmacological profiles or evidence bases). However, clinicians must never refuse to consider other products solely because they are not on an internal clinic list, without clinical reasoning. [1]
Clinical judgement during prescribing must always focus on the patient's individual needs rather than operational convenience or commercial preference. This is consistent with all prescribing guidance for individualised care.
Do's for Clinicians
- Respect patient choice of pharmacy — inform patients they may take their prescription to any appropriately registered pharmacy capable of dispensing CBPMs
- Provide balanced product information — discuss evidence, risks, benefits, and availability of relevant CBPMs to enable informed decision-making
- Explain formulary limits transparently — if prescribing experience is concentrated on certain products, clarify this and discuss why other products may be clinically appropriate
- Follow GMC prescribing standards — ensure decisions are based on clinical evidence and patient needs, not commercial relationships [1]
- Operate within CQC governance expectations — maintain transparency in prescribing practices and avoid commercial influence on clinical decision-making [4]
Don'ts for Clinicians
- Do not require patients to use a particular pharmacy for non-clinical reasons
- Do not imply that prescriptions are "owned" by the clinic or that patients must dispense through a preferred partner
- Do not limit prescribing to products on an internal formulary if other products are clinically suitable and available
- Do not allow commercial arrangements with pharmacies or manufacturers to influence clinical prescribing choices
Any practice that restricts patient choice on non-clinical grounds may undermine professional ethics and patient trust.
Your rights as a CBPM patient
What you are entitled to
- You have the right to choose the pharmacy that dispenses your prescription, provided it is registered and authorised to supply controlled drugs and CBPMs [5]
- A prescription is your legal document, it may be taken to any suitable registered pharmacy
- Clinicians must explain the clinical basis for any recommended product, including risks and benefits, to support informed consent
- You have the right to ask questions about alternative products that may suit your needs, clinicians cannot refuse without clinical reasoning
- You may seek an independent clinical opinion if you feel your product options are being unduly restricted
Steps to take if you feel directed unfairly
Ask for clarification
Request a clear clinical explanation for why you are being directed to a specific pharmacy or product. This is your right as a patient and an essential part of informed consent.
Request that your prescription is honoured at a pharmacy of your choice
If there is no clinical reason preventing this, your prescriber should issue a prescription you can take to your preferred registered pharmacy.
Seek an independent clinical opinion
If you feel your product choice is being unduly limited, another CBPM specialist may be able to assess your case and consider alternatives that better meet your clinical needs.
Contact professional regulators
If you believe professional standards are not being upheld, contact the GMC (for doctors) or the Care Quality Commission (for independent providers). Both bodies take concerns about prescribing conduct seriously. [4]
Best practice at a glance
| Area | For Clinicians | For Patients |
|---|---|---|
| Pharmacy choice | Respect the patient's right to choose any registered pharmacy | Know you own your prescription and can choose your pharmacy |
| Product selection | Provide evidence-based product discussions; only restrict based on clinical grounds | Ask questions about product options; clinicians must explain their reasoning |
| Formulary limits | Be transparent about which products are most familiar to you and why | Seek alternative clinical advice if your options feel unduly limited |
| Commercial interests | Ensure no commercial arrangements influence prescribing decisions | Ask directly whether your clinic has a commercial relationship with a pharmacy |
| Regulatory compliance | Meet CQC expectations; document clinical justification for all prescribing decisions | Contact the GMC or CQC if professional standards appear to be breached |
Why this matters now
The private CBPM sector has grown rapidly since 2018. With more clinics and dispensing pharmacies than ever before, clarity on prescription rights protects patients and upholds professional standards across the entire pathway.
CPD-approved content
PatientsCann UK is a CPD-approved provider (reference 790169). This guidance article is published for educational purposes and reflects current regulatory frameworks for clinicians and patients navigating CBPMs in the UK.
References
- General Medical Council (2026) Information for doctors on Cannabis-based products for medicinal use (CBPMs). GMC. Available at: gmc-uk.org/professional-standards/learning-materials/… (Accessed February 2026).
- National Institute for Health and Care Excellence (2025) Cannabis-based medicinal products: recommendations. NICE. Available at: nice.org.uk/guidance/ng144/chapter/Recommendations (Accessed February 2026).
- NHS England (2023) Cannabis-based products for medicinal use (CBPMs) — frequently asked questions. NHS England. Available at: england.nhs.uk/medicines-2/support-for-prescribers/… (Accessed February 2026).
- Care Quality Commission (2024) Cannabis-based medicinal products: what CQC expects from providers. CQC. Available at: cqc.org.uk/guidance-providers/healthcare/cannabis-based-medicinal-products-… (Accessed February 2026).
- Pharmaceutical Regulation Authority (2025) Registered pharmacies providing cannabis-based products for medicinal use. Available at: pharmacyregulation.org/files/2025-10/Registered-pharmacies-… (Accessed February 2026).
Questions about your prescription rights?
PatientsCann UK is a patient-led Community Interest Company. If this guidance raises questions about your current prescription, your rights as a patient, or accessing medical cannabis for the first time, our free resources can help you understand your options.
Written By
Mohammad Ismail "Ish" Wasway · Managing Director
PatientsCann UK® · Education · Published 23 March 2026
PatientsCann UK is a patient-led Community Interest Company (CIC). All content is produced for educational purposes. CPD Provider Reference: 790169.
